Axon Ligands (TM) - alphabetic: [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z]

ABT 869  -  Linifanib

CAS 796967-16-3

C21H18FN5O MW 375.40

Purity: 99%

Soluble in DMSO to 40 mM 

Ordering Information:

Cat. No. Axon 1638    Prime Source

Qty1: 5 mg (research sample) / €95  $124 

Promotion: 2 x 5 mg / €140  $182   

Qty2: 25 mg  (research sample) / €285  $371 

Promotion: 50 mg / €400  $520   

Qty3: on request

Send enquiry to: order@axonmedchem.com

or by fax to: +31-50-3600390.

Contact us for payment and tech support.

Biological Activity:   A multi-targeted receptor tyrosine kinase (RTK) inhibitor, targeting VEGRFs, PDGFRs, Fms-like tyrosine kinase-3 and c-KIT. In cellular assays ABT869 inhibits RTK phosphorylation (IC50 = 2, 4, and 7 nM for PDGFR-β, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC50 = 0.2 nM for human endothelial cells).   References: online   DH Albert et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 2006, 5, 995-1006. [online]   J Zhou et al. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J. Hematol. Oncol. 2009, 2, 33. [online]   AK Ikeda et al. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol. Cancer Ther. 2010, 9(3), 653-60. [online]     Chemical Name: N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea

ABT 869 - Linifanib | RTK inhibitor | Axon Medchem | Axon 1638 | ABT869

Axon Ligands ^TM - Research chemicals for biological study. Some high-profile samples could be provided under terms of contract research synthesis.

axonmedchem.com © 2012

Axon Ligands In The Field: